TY - JOUR T1 - <em>In vivo</em> demonstration of microvascular thrombosis in severe Covid-19 JF - medRxiv DO - 10.1101/2020.07.09.20149971 SP - 2020.07.09.20149971 AU - Douglas Alexandre do EspĂ­rito Santo AU - Anna Cristina Bertoldi Lemos AU - Carlos Henrique Miranda Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/11/2020.07.09.20149971.abstract N2 - Several autopsies studies showed the presence of microthrombi in the pulmonary circulation of the severe COVID-19. The major limitation of these investigations is that the autopsy provided static information. Some of these alterations could be secondary to the disseminated intravascular coagulation (DIC) observed as the final common pathway of the multisystem organ failure exhibited in the critical patient. We report the preliminary results of an in vivo evaluation of the sublingual microcirculation in thirteen patients with severe COVID-19 requiring mechanical ventilation at the beginning of the hospitalization. They did not have any laboratorial DIC evidence. We observed multiple filling defects moving within the sublingual microvessels indicative of microthrombi in 11 (85%) patients. This is the first imaging documentation of microvascular thrombosis in living patients with severe COVID-19. The clinical relevance of microvascular thrombosis in this disease requires further research.HighlightsThe presence of microthrombi in the pulmonary circulation is a common finding in autopsies of severe COVID-19.In vivo evaluation of the sublingual microcirculation of severe COVID-19 showed multiple filling defects moving within the microvessels indicative of thrombi in most of these patients.This is the first imaging documentation of microvascular thrombosis in living patients with severe COVID-19.The clinical relevance of microvascular thrombosis in COVID-19 requires further research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by grants of the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), process number: 2019/06187-1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Research Ethics Committee of our institution and followed the Declaration of Helsinki. (Approval number: 4.000.967)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used and/or analyzed during the current study are available from the corresponding author on reasonable request. ER -